In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced ...

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Novocure NVCR recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...